XCancer

Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies

Description:

The purpose of this study is to investigate the safety and potential effectiveness of the imaging compound 18F FPM for finding sites of malignancies.

Sponsor:

Peter MacCallum Cancer Centre

Phase:

Early Phase 1

Contacts:

Ben Solomon (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT01755650 - Click here to see study on

ClinicalTrials.gov

FPM

Isotope(s):
Target(s):
  • Amino Acid Transport
Inclusion
  • * Written informed consent obtained prior to any protocol-specific procedures
  • Life expectancy \>/= 3 months
  • At least one site of active malignancy, as demonstrated on the pre-study 18F FDG PET/CT scan performed as part of routine clinical care
  • Male and female patients with histologically confirmed squamous cell carcinoma
  • Age \>/= 18 years
Exclusion
  • Patients unwilling or unable to comply with protocol or with a history of non-compliance or inability to grant informed consent
  • Any serious medical condition which the investigator feels may interfere with the procedures or evaluations of the study
  • Systemic anti-neoplastic therapy within the 2 weeks prior to the pre-study 18F FDG PET/CT scan until after the 18F FPM PET/CT scan
  • * Pregnant or breastfeeding females